Trial · NCT07886190
Symptom Monitoring and Management Intervention After CAR-T
NCT07886190, Not applicable, Not yet recruiting, Massachusetts General Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Symptom Monitoring and Management Intervention After CAR-T. Trials, record NCT07886190. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07886190
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Symptom Monitoring and Management Intervention After CAR-T
- NCT number
- NCT07886190
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 65 participants, estimated
- Lead sponsor
- Massachusetts General Hospital
- Conditions
- Chimeric Antigen Receptor T-cell Therapy, Hematologic Malignancy
- Interventions
- WAYPOINT
- First posted
- 2026-10-21
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Feasibility of the intervention: percentage of eligible patients who enroll and remain in the study by day 90 | Up to 90 days post enrollment | The investigators will assess feasibility based on the percentage of eligible patients who enroll and the percentage of enrolled patients who remain in the study through day 90. The intervention will be considered feasible if at least 60% of eligible patients enroll and at least 70% of enrolled patients remain in the study through day 90. |
| Primary | Acceptability of the intervention: percentage of participants report satisfaction when using the intervention. | Up to 90 days post-enrollment | The investigators will assess acceptability by examining the percentage of patients and clinicians who report satisfaction with WAYPOINT. The intervention will be considered acceptable if at least 80% of patients and at least 80% of clinicians report satisfaction with WAYPOINT. For patients, a score =\>20 on the 8-item Client Satisfaction Questionnaire (CSQ-8; range of scores 8-32) will indicate acceptability. For clinicians, a score =\> 3 on the item "How acceptable is the intervention for you" (score range, 1-5) will indicate acceptability. |
| Other | Ease of use of WAYPOINT as measured by the System Usability Scale (SUS) questionnaire | Up to 90 days post enrollment | Describe ease of use of WAYPOINT as measured by the SUS. The SUS ranges from 0-100 and higher scores indicate greater ease of use. |
| Other | Symptom burden as measured by the Edmonton Symptom Assessment Scale-revised (ESAS-r) questionnaire | Up to 90 days post enrollment | Describe patient symptom burden as measured by the ESAS-r. The ESAS-r ranges from 0-100 and higher scores indicate worse symptom burden. |
| Other | Depressive symptoms as measured by the Hospital Anxiety and Depression Scale (HADS-Depression) | Up to 90 days post enrollment | Describe patient depression symptoms as measured by the HADS-Depression. The HADS-Depression ranges from 0-21 and higher scores indicate worse depressive symptoms |
| Other | Anxiety symptoms as measured by the Hospital Anxiety and Depression Scale (HADS-Anxiety) | Up to 90 days post enrollment | Describe patient anxiety symptoms as measured by the HADS-Anxiety. The HADS-Anxiety ranges from 0-21 and higher scores indicate worse anxiety symptoms |
| Other | Self-efficacy as measured by the Cancer self-efficacy (CASE) scale | Up to 90 days post enrollment | Describe patient self-efficacy as measured by the CASE. The CASE ranges from 0-170 and higher scores indicate better self-efficacy |
| Other | Patient quality of life (QOL) as measured by the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire | Up to 90 days post enrollment | Describe patient QOL as measured by the FACT-G. The FACT-G ranges from 0-108 and higher scores indicate better QOL |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R41CA314618 | Improving patient outcomes through a digital health delivered intervention to monitor and manage symptoms after chimeric antigen receptor T-cell therapy | Landau, Daniella; Barata, Anna | MCC HEALTH, INC | NATIONAL CANCER INSTITUTE | 2026 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07886190
GET https://conductscience.org/api/trials/v1/NCT07886190/registered